Retina International World Congress 2020 - Preliminary sessions program.

Session labelling: K= Keynote – L= Lay - P = Professional

Thursday 4th June
17:00 – 19:00 Welcoming ceremony
Prof. Mark S. Humayun University of Southern California, Los Angeles, USA

Friday 5th June
08:30 – 10:00 P.2.1 Age related macular Degeneration.
Moderator: Dr. Øystein Kalsnes Jørstad, Oslo University

08:30 - 08:50: A systems level investigation on AMD: Insights from the European EYE-RISK project
Speaker: Professor Marius Ueffing, Centre for Ophthalmology, University Medical Center, Tuebingen, Germany

08:50 - 09:05: AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy
Speaker: Professor Morten Carstens Moe, Oslo University Hospital, Oslo, Norway

09:05 - 09:15: Off-label use of Avastin: Scandinavian disparities
Speaker: Tomas Bro, MD, PhD, Höglandssjukhuset, Eksjö, Sweden

09:15-09:25: The risk of extending AMD treatment
Speaker: David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden

09:25 - 09:35 The Swedish Macula Register
Speaker: Inger Westborg, MD, PhD., Uppsala University Hospital, Uppsala, Sweden

09:35 - 09:50 AMD Epidemiology and Genetics. What is important!
Speaker: Prof. Emeritus Friðbert Jónasson, University of Iceland, Iceland:

09:50 - 10:00: QnA

08:30 – 10:00 L.2.1 Retinal degenerations. Clinical aspects.
Moderator: Dr. Prof. Elise Heon, The Hospital for Sick Children, Toronto, Canada.
08:30 – 08:50: Clinical aspects of IRD
Speaker: Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada

08:50 - 09:10: Clinical aspects of inherited macular degenerations.
Speaker: Dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.

09:10 - 09:30 Usher syndrome and similar syndromic forms of IRD.
Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France

09:30 - 09:50: The socio-economic impact of IRDs
Speaker: Dr. Orla Galvin, Retina International, Dublin, Ireland

09:50 – 10:00 QnA.

10:00 – 10:30 Coffee break.

10:30 – 11:30 P.2.2 Assessment of Endpoints in clinical studies.
Moderators Dr. Cecilie Bredrup, Bergen, Norway and Prof. Sten Kjellström, Lund, Sweden.

10:30 – 10:50: How to measure the effects of gene therapy on meaningful vision for patients
Speaker: Prof. Michael Larsen Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark:

10:50 – 11:10 Paediatric specificities in trials
Speaker: Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada

11:10 – 11:30: Developing Patient Relevant Outcomes in Gene Therapy Trials: The Novel Functional Vision Endpoint, the Multi-luminance Mobility Test (MLMT)
Speaker: Dr. Daniel Chung, DO, MA, Spark Theraeutics, Philadelphia, USA

10:30 – 11:30 L.2.2 Retinal degenerations - the genetics.
Moderator: Prof. Jón Jóhannes Jónsson, national University Hospital, Reykjavík, Iceland.

10:30 – 10:50: Pattern of inheritance - easy to understand.
Speaker: Dr. Eirný Pórólfsdóttir National University Hospital, Reykjavík, Iceland.
10:50 – 11:10: Understanding the results - a difficult task.
Speaker: Prof. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland.

11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes.
Speaker: Daniel Porsteinsson

Speaker: Avril Daly, Retina International, Dublin, Ireland

11:30 – 12:00 K.2.1 Keynote: Scientific results, a rollercoaster between hope and deception
Speaker: Christina Fasser, president of Retina International, Zurich (Switzerland)

12:00 – 13:30 Lunch

13:30 – 14:00 K.2.2 Keynote: Phenotyping and Genotyping in inherited retinal diseases.
Speaker: Prof. Bart Leroy, University of Ghent, Gent, Belgium

14:00–15:00 P.2.3 Phenotyping and Genotyping in IRD.
Moderators: Josephine Prener Holtan MD, Oslo University Hospital, Oslo, Norway, and
Prof. Bart Leroy, Ghent, Belgium.

14:00 – 14:10: Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene
Speaker: Dr. Kristian Lisbjerg, Copenhagen University Hospital, Denmark

14:10 – 14:20: Genetic basis and phenotypic characterization of Danish patients with Achromatopsia.
Speaker: Dr. Mette K.G. Andersen, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark

14:20 – 14:30 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective
Speaker: Prof. Ragnhild janson Wives tad, Haukeland University Hospital, Norway

14:30 – 14:50 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe
Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France:
14:50 – 15:00 QnA
14:00 – 15:00 L.2.3 Basics of stem cell and gene-based therapies.
Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA

14:00- 14:20 Overview of on-going clinical trials with stem cells
Speaker: Prof. Goran Petrovski

14:20 – 14:35 Stem cell trial on Retinitis pigmentosa.
Speaker: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA

14:35 – 14:50 Clinical trial in opto-genetics.
Speaker: Prof. Isabelle Audo, INSERM, Paris, France

14:50 – 15:00 How to discriminate between real treatments offers and quacks.
Speaker: Martin Smedstad Oslo, Norway.

15:00 – 15:30 Coffee break.

15:30 – 16:00 K.2.3 Keynote: Innovations in Ophthalmology.
Prof. Eugene De Juan University of California, San Francisco, USA.

16:00 – 17:00 P.2.4. Innovations in Ophthalmology
Moderators: Christina Fasser and Prof. Einar Stefánsson.
Speakers: Dr. Sabri Markabi, MD Senior vice president of Research and Development and Chief Medical Officer of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company.Prof. Einar Stefánsson, , National University Hospital in Iceland. Kathrine A. High, Emeritus co-founder, president and chief scientific officer of Spark. To be confirmed.

16:00 – 17:00 L.2.4 Rehabilitation and mobility training.
Moderators: Vala Jóna Garðarsdóttir and Rosa María Hjörvar Iceland.

16:00 - 16:15: Mobility training and mobility tools

16:15 – 16:30 Reading with auxiliary aids
Speaker: Rósa María Hjörvar. PhD student in Literature at the University of Iceland

16:30-16:45: The assistive technology, aps etc.
Speakers: Baldur Snær Sigurðsson and Hlynur Pór Agnarsson
16:45 - 17:00: Coping with visual and hearing impairment:
Speakers: Halla Dís Hallfreðsdóttir and Elín Yr. Hafdisardóttir Arnardóttir.

Saturday 6th June

08:30–10:00 P.3.1 Preparing for clinical trials in IRD.
Moderator: Prof. Michael Larsen.
Speakers to be confirmed

08:30-10:00 L.3.1 Clinical trials and therapies from a patient’s perspective.
Moderator: Martin Smedstad, Oslo, Norway.

08:30 – 08:50 Overview and future on on-going clinical trials Speaker Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada

08:50 – 09:10: RPE65 - the first gene therapy on the market
Speaker: Dr. Daniel Chung, DO, MA, Spark Therapeutics, Philadelphia, USA.

09:10 – 09:30 Oligonucleotides - a hope for all?
Speaker: Prof. Bart Leroy, Gent University, Ghent, Belgium

09:30 – 09:50 My personal experience with a clinical trial
Speaker: to be confirmed.

10:00 – 10.30 Coffee break.

10:30 – 12:00 P.3.2 Stem cells and cell-based therapies of retinal diseases.
Moderator Dr. Goran Petrovski, Oslo, Norway.

10:30 – 10:45: Initiating a Phase I/IIa clinical trial for an autologous iPS cell therapy for macular degeneration: from bench-to-bedside.
Speaker: Prof. Kapil Bharti (NIH/NEI), Bethesda, USA.

10:45 – 11:00 Towards stem cell-based therapies in retinal degenerations
Speaker: Anders Kantar (Stockholm, Sweden

11:00 – 11:30 Subretinal implantation of primary human RPE cells in minipig eyes.
Speaker: Dr. Goran Petrovski, Oslo, Norway.

11:30 – 12:00 Epigenetic characterization during differentiation from iPS to RPE cells in AMD.
Speaker: Dr. Cristina Zibetti (Oslo, Norway)
10:30 -12:00 L 3.2 Retina International - the global challenges
Moderator: Kristinn Halldor Einarsson, Iceland
Speakers: Christina Fasser, Avril Daily.
Other speakers to be confirmed.

12:00-13:00 Lunch

13:00 – 14:00 K.3.1 Keynote: Gene based therapies of retinal diseases.
Speaker: Prof. Arthur Cideciyan, University of Pennsylvania, Philadelphia, USA.

14:00 – 15:00 P.3.3 Gene based therapies of retinal diseases.
Moderator Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland

14:00 – 14:15 CPK850 gene therapy in RLPB1 patients.
Speaker: Prof. Anders Kantar, Karolinska Institute, Stockholm, Sweden

14:15 – 14:30 Retinal gene therapy trials - investigators point of view Speaker: Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland

14:30 – 14:45 Retinal gene therapy in choroideremia patients - surgical aspects.
Speaker: Prof. Ilkka Immonen, Helsinki University Hospital, Helsinki, Finland

14:45 – 15:00 Gene therapy of Usher syndrome. Speaker: Prof. Isabelle Audo, Institute de la Vision, Paris, France

14:00-15:00 L.3.4 Programme in Islandic for the public.
Moderator: Dr. Sigríður Másdóttir, Reykjavík, Iceland.

15:00 – 15:30 Coffee break.

15:30 – 17:00 K.3.3 What the future holds: Panel discussion (AMD, IRD, genetics, Innovation)

17:00–17:30: K.3.4 What have we learned?
Speaker: Prof Emeritus Gerald G. Chader, Los Angeles, USA

17:30 – 18:00 Closing ceremony.